WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998051298) ARYLSUBSTITUTED PIPERAZINES USEFUL IN THE TREATEMENT OF BENIGN PROSTATIC HYPERLASIA
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1998/051298 International Application No.: PCT/US1998/009023
Publication Date: 19.11.1998 International Filing Date: 08.05.1998
Chapter 2 Demand Filed: 11.12.1998
IPC:
C07D 207/27 (2006.01) ,C07D 207/28 (2006.01) ,C07D 209/48 (2006.01) ,C07D 211/76 (2006.01) ,C07D 223/10 (2006.01) ,C07D 295/13 (2006.01)
Applicants: ORTHO-McNEIL PHARMACEUTICAL INC.[US/US]; U.S. Route 202 Raritan, NJ 08869-0602, US
Inventors: JOLLIFFE, Linda; US
MURRAY, William; US
PULITO, Virginia; US
REITZ, Alan; US
LI, Xiaobing; US
MULCAHY, Linda; US
MARYANOFF, Cynthia; US
VILLANI, Frank; US
Agent: CIAMPORCERO, Audley, A., Jr. ; Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933, US
Priority Data:
60/046,23612.05.1997US
Title (EN) ARYLSUBSTITUTED PIPERAZINES USEFUL IN THE TREATEMENT OF BENIGN PROSTATIC HYPERLASIA
(FR) PIPERAZINES A SUBSTITUTION ARYLE UTILES DANS LE TRAITEMENT DE L'ADENOME PROSTATIQUE
Abstract: front page image
(EN) This invention relates to a series of arylsubstituted piperazines, of Formula (I), pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the $g(a)-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.
(FR) L'invention concerne une série de pipérazines à substitution aryle, de formule (I) et des compositions pharmaceutiques renfermant ces pipérazines ainsi que des intermédiaires utilisés dans leur élaboration. Les composés décrits inhibent de manière sélective la liaison sur adrénorécepteur $g(a)-1a, un récepteur intervenant dans l'adénome prostatique. En tant que tels, lesdits composés ont une utilité potentielle dans le traitement de l'adénome considéré et d'autres affections.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)